Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
78.6M
-
Shares change
-
+1.27M
-
Total reported value, excl. options
-
$622M
-
Value change
-
+$4.1M
-
Put/Call ratio
-
1.15
-
Number of buys
-
79
-
Number of sells
-
-80
-
Price
-
$7.92
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q4 2022
199 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q4 2022.
Coherus Oncology, Inc. - Common Stock (CHRS) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.6M shares
of 115M outstanding shares and own 68.09% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.1M shares), Temasek Holdings (Private) Ltd (7.38M shares), STATE STREET CORP (6.79M shares), JPMORGAN CHASE & CO (6.5M shares), ALLIANCEBERNSTEIN L.P. (6.22M shares), VANGUARD GROUP INC (5.82M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.09M shares), AMERIPRISE FINANCIAL INC (1.83M shares), and CITADEL ADVISORS LLC (1.31M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.